News that AbbeVie’s (ABBV) Humira drug was granted FDA orphan designation for treatment of non-infectious intermediate posterior pan-uveitis or chronic non-infectious anterior uveitis moved the stock up in yesterday’s trading.
Your May $52.50 options (ABBV140517C00052500) also jumped 46.34%. Sadly, this wasn’t enough for your options to be profitable.
So sell your May $52.50 call options at a loss today before they expire worthless tomorrow.
In addition, I am recommending that you close your position in Thermo Fisher Scientific (TMO) at a slight gain as that stock has lost momentum since peaking in early March.
This content is for paid subscribers only. To gain access subscribe to one of our…
It is hard to find a seasoned investor who doesn’t believe the stock market is…
No one believes a financial disaster can strike… until it’s too late. That’s bizarre, considering…
The Options Industry Council is a resource used to educate investors about the benefits and…
The put-call parity is the relationship that exists between put and call prices of the…
“It’s not a stock market, it’s a market of stocks.” -- “Maxims of Wall Street,”…